Jump to content

Sunifiram

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by GKantaris (talk | contribs) at 09:54, 7 March 2017 (Added study showing AMPA-r activation in the anti-amnesiac effects of sunifiram). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Sunifiram
Legal status
Legal status
  • US: Not FDA approved; unscheduled
Identifiers
  • 1-Benzoyl-4-propanoylpiperazine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC14H18N2O2
Molar mass246.304 g/mol g·mol−1
3D model (JSmol)
  • CCC(=O)N1CCN(CC1)C(=O)c2ccccc2
  • InChI=1S/C14H18N2O2/c1-2-13(17)15-8-10-16(11-9-15)14(18)12-6-4-3-5-7-12/h3-7H,2,8-11H2,1H3 ☒N
  • Key:DGOWDUFJCINDGI-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Sunifiram (DM-235) is a piperazine derived research chemical which has anti-amnesiac effects in animal studies with significantly higher potency than piracetam.[1] Sunifiram is closely related to, and derived from, unifiram. The anti-amnesiac effect of both chemicals has been shown to involve AMPA-receptor activation.[2]

As of 2017 it had not been subjected to toxicology testing, nor to any human clinical trials, and is not approved for use anywhere in the world.[1]

References

  1. ^ a b Gualtieri F (2016). "Unifi nootropics from the lab to the web: a story of academic (and industrial) shortcomings". Journal of Enzyme Inhibition and Medicinal Chemistry. 31 (2): 187–94. doi:10.3109/14756366.2015.1021252. PMID 25831025.
  2. ^ Galeotti, N.; Ghelardini, C.; Pittaluga, A.; Pugliese, A.; Bartolini, A.; Manetti, D.; Romanelli, M.; Gualtieri, F. (2003). "AMPA-receptor activation is involved in the antiamnesic effect of DM 232 (unifiram) and DM 235 (sunifiram)". Naunyn-Schmiedeberg's archives of pharmacology. 368 (6): 538–545. doi:10.1007/s00210-003-0812-6. PMID 14600801.

Template:Nootropics